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A B S T R A C T
Lung cancer is the most frequent malignant disease and the leading cause of death from malignant diseases in the
world and its incidence is increasing. At the time when diagnosis is established most patients have advanced disease and
are not candidates for radical surgical treatment. Patients without distant metastases are subjected to various diagnostic
methods to detect metastases in mediastinal lymph nodes that make up the path of lymph drainage from the lungs. The
most reliable invasive diagnostic procedures for detecting metastases in mediastinal lymph nodes are videomediastinos-
copy and endobronchial ultrasound with transtracheal puncture. In the absence of mediastinal lymph node metastases
surgery is the treatment of choice. If mediastinal lymph nodes are positive for metastases multimodal treatment is imple-
mented. At the Department of Thoracic Surgery, Zadar General Hospital, videomediastinoscopy for the staging of pri-
mary non-small cell lung cancer has been performed routinely since September 2009.
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Introduction
Lung cancer is the leading cause of death from malig-
nant diseases worldwide and its incidence is increasing.
In 2008. in the United States 215 000 people were diag-
nosed with lung cancer and 161 840 died. More people die
annually from lung cancer than from breast, colon and
prostate cancer together1,2.
Five years survival rate in patients suffering from lung
cancer is increasing slowly; in 1976. it was 11.9%, and in
2000. it was 15%. The main reason for the poor survival
lies in the fact that 40% of patients have metastatic dis-
ease at the moment when diagnosis is established3.
In patients diagnosed with lung cancer it is necessary
to carry out diagnostic evaluation to determine the stage
of disease. Staging provides adequate information about
the spread of the disease and it is crucial for determining
the strategy of treatment and prognosis4. Staging is used
for non – small cell lung cancer. For small cell lung can-
cer, which occurs in 10–15% of cases, invasive staging is
not performed because this tumor has different biologi-
cal features and is rarely subject of surgical treatment.
In the absence of distant metastases, involvement of
mediastinal lymph nodes is the most important prognos-
tic factor in patients with non-small cell lung cancer and
mediastinal lymph node status determines the treatment
strategy.
Primary surgical treatment of lung cancer with meta-
stases to ipsilateral mediastinal lymph nodes (stage IIIA)
gives poor results. Patients who were subjected to pri-
mary surgical treatment in stage IIIA have a five year
survival rate of
7–14%5. Adjuvant chemotherapy often can not be
completed because of poor general condition of patients
who are recovering from surgery6.
Neoadjuvant Treatment
Chemotherapy, radiation or a combination of both
methods are used as neoadjuvant treatment7. Neoadju-
vant therapy offers several potential advantages. Theo-
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retically, it acts on tumor cells before they produce resis-
tant clones7. Patients can also receive full doses of drugs
because they are not in postoperative recovery phase. In
such conditions therapy often results in tumor reduction
and eradication of the disease from mediastinal lymph
nodes6–8.
If neoadjuvant therapy eradicates the disease in lymph
nodes (downstaging) or if there is no progression of dis-
ease, patients are rendered candidates for surgical treat-
ment9. After implementation of neoadjuvant therapy and
surgery, the five-year survival rate for patients with
stage III A disease is about 25%6–9.
Staging of Disease
The international system for staging of lung cancer is
based on assessement of the extent of the primary tumor
(T), the spread to the regional lymph nodes (N) and of
the presence of distant metastasis (M).The combination
of T, N and M is than used to determine the stage of dis-
ease (I–IV). The last revision of the TNM classification of
lung cancer was in 200910.
Status of mediastinal lymph nodes is the most impor-
tant factor that determines treatment strategy. It is also
used to evaluate efficiency of neoadjuvant therapy7.
For clinical work it is necessary to map lymph nodes
in the mediastinum at nodal positions.
This kind of map was developed by Mountain and
Dresler12 and accepted by all relevant world organiza-
tions dealing with the treatment of lung cancer7,11,13.
According to this map mediastinal lymph nodes are
located in nine nodal positions while five other nodal po-
sitions are located in the lungs. Each nodal position is
precisely defined anatomically.
There are several types of staging. The two principal
ones are:
– clinical (non-invasive): cTNM
– pathological (invasive): pTNM
Noninvasive Staging
Clinical staging is based on history, physical examina-
tion, laboratory findings and radiological evaluation14.
Radiological Evaluation
All patients who are suspected to have lung cancer
should have a chest X-ray. It serves as the basis for com-
parison with further scans.
Standard chest X-rays can reveal signs of advanced
disease (eg. pleural effusion, secondary lesions in the
lung parenchyma, destruction of the ribs and elevated di-
aphragm which indicates involment of phrenic nerve)14.
Computed Tomography – CT
CT scan allows much better visualization of intratho-
racic status. Besides determining tumor size, media-
stinal and vascular invasion and involment of airways, it
can also suggest lymph node involvement. Disadvantages
of CT staging are the inability to distinguish benign from
malignant mediastinal lymphadenopathy and the inabil-
ity to detect microscopic metastases. According to CT cri-
teria, lymph node is suspicious to metastases if its short-
-axis diameter is greater than 10 mm. Sensitivity of this
method is 57–70% and specificity of 59–82%14.
Integrated Positron Emission Tomography –
Computed Tomography (PET-CT)
This method can detect occult disease. Lung cancer
cells have an increased metabolism and therefore receive
increased Fluoro-Deoxy-Glucose (FDG). By PET criteria
lymph node is considered metastatic if its metabolic ac-
tivity is increased 1.5 times compared to baseline. This
method has a sensitivity of 90%. Despite this high sensi-
tivity histological confirmation of metastases is requred
due to its low specificity. Inflammation and infection can
give false positive results which can result in upstaging15.
Invasive Staging
There are controversies about the definition of patho-
logical staging. Some believe that the pathological stage
of disease can be established only after surgical explora-
tion of hemithorax and mediastinum.
Others accept that the pathological stage can be de-
termined based on tissue samples obtained by invasive
diagnostic methods7.
Videomediastinoscopy
Because of high sensitivity (90%), low percentage of
false negative results (10%) and rare complications, vi-
deomediastinoscopy is recommended by the European
Society of Thoracic Surgeons (ESTS), as the »gold stan-
dard« for invasive staging of lung cancer11.
It is performed under general anesthesia. The patient
is placed in supine position with the neck extended. The
incision is made transversely 1 cm above the jugulum.
After the incision of the pretracheal fascia an optical-
-working instrument – videomediastinoscope (Richard
Wolf, Germany) is introduced. With bimanual technique
of preparation the upper mediastinum lymph nodes are
exposed.
By cervical videomediastinoscopy following nodal po-
sitions can be sampled: high mediastinal lymph nodes
(group 1), left and right upper paratracheal (group 2L
and 2R), left and right lower paratracheal (group 4L and
4R) and subcarinaln lymph nodes (group 7).
There are no internationally accepted recommenda-
tions considering the number of nodal stations that
should be retrieved during cervical mediastinoscopy.
American Association of Thoracic Surgeons (ATS)
recommends that all available nodal positions should be
sampled. It includes lymph nodes at nodal positions 2L,
2R, 4L, 4R, 7, 10 L and 10 R (left and right tracheo-
bronhal). The recommendation is to perform left para-
sternal mediastinothomy for lymph node sampling at
nodal positions 5 and 6 (subaortal and anterior mediasti-
nal) in patients with cancer of left lung11.
Working Group of the European Association of Tho-
racic Surgeons (ESTS) states that there are two stan-
dards for mediastinoscopy:
¿ sampling of lymph nodes from nodal positions 2L,
2R, 4L, 4R and 7 should be performed.
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¿ for routine clinical practice lower standard can be
accepted which includes sampling of lymph nodes
at nodal positions 4L, 4R, and 7.
In patients with left lung cancer it is necessary to
sample lymph nodes in positions 5 and 6 (subaortal and
anterior mediastinal)11.
In these cases, cervical approach is complemented
with Chamberlain’s anterior mediastinothomy or VATS
or extended mediastinoscopy is performed within the
plane of the dissection in the area in front of the aortic
arch and its branches14.
The advantage of mediastinoscopy compared to fine-
-needle aspiration biopsy (FNA), is that it can gain more
complete insight into the status of lymph nodes in media-
stinum including the contralateral side. This may be sig-
nificant in patients with metastases in lymph nodes of
one nodal station. It allows differentiation of extra and
intracapsular metastasis and it also allows differentia-
tion of nodal metastasis and direct tumor invasion16.
Complications of videomediastinoscopy are bleeding
from large mediastinal blood vessels, pneumothorax, re-
current laryngeal nerve injury, injury of the esophagus
and trachea and bronchial injury. Complications occur
very rarely (2%). Most severe complications resulting in
death occur in 0.008% of cases7,15.
The sensitivity of cervical mediastinoscopy ranges
from 72 to 89%. The reason for suboptimal sensitivity of
cervical videomediastinoscopy lies in the fact that some
nodal positions (5, 6, the posterior parts of group 7, 8,
and 9) are not reachable with videomediastinoscopy11.
In 2007. Kuzdzal et al. compared standard mediasti-
noscopy to extended transcervical mediastinal lymph-
adenectomy (VAMLA) and demonstrated increased sen-
sitivity in detecting metastases to mediastinal lymph
nodes using VAMLA. It is a technique of extended dissec-
tion of mediastinal lymph nodes and requires special in-
struments. VAMLA has a sensitivity of 94% and specific-
ity of 100%17.
These preliminary data suggest that VAMLA com-
bined with R0 resection could have a positive therapeutic
effect. Besides somewhat more intensive postoperative
pain incidence of complications is not higher when com-
pared to standard cervical videomediastinoscopy.
In patients with left lung cancer more aggressive
TEMLA (transcervical extended mediastinal lymphade-
nectomy) can be performed. This technique requires ele-
vation sternum, dissection is done in front of the aortic
arch, and lymph nodes of nodal groups 1, 2L, 2R, 3, 4L,
4R, 5, 6, 7 and 8 are reachable18,19.
Anterior Mediastinotomy by Chamberlain
Predilective lymph nodes for metastatic cancer of the
left upper lobe are those at nodal position 5 (subaortal).
With the incision in the second or third intercostal space
these lymph nodes can be accessed. This method is usu-
ally performed in addition to mediastinoscopy for cancer
of the left upper lobe15.
VATS (Video assisted thoracoscopic surgery)
Video-assisted thoracoscopic surgery can be used for
sampling of mediastinal lymph nodes. It is limited to
evaluating only one side of the mediastinum. Because of
low sensitivity (50%) it is rarely used for the evaluation
of mediastinal lymph nodes21,22.
Flexible Bronchoscopy
It is an endoscopic method for visualization of bron-
chial tree and sampling using endobronchal biopsy, sam-
pling brush and bronchial lavage.
Blind Transbronchial Fine Needle
Aspiration Cytology (TBNA)
It is also known as Wang’s method. It is commonly
used for sampling of subcarinal lymph nodes (group 7).




To perform this method a flexible bronchoscope
equipped with convex ultrasound probe is used in order
to enable visualisation of lymph nodes before the needle
biopsy. Nowdays,besidses invasive mediastinoscopy, it is
the most relevant method for mediastinal lymph node
staging. The issue whether this method is as reliable as
videomediastinoscopy for invasive staging is not solved
yet. There is also controversy about the claims that it is
less invasive because in over 60% of cases EBUS-TBNA
is performed under general anesthesia. Otherwise it is
difficult to collect adequate samples because patients are
restless, the procedure is very uncomfortable and the
materials taken with a small diameter needle may result
in an inadequate intake of the sample and produce false
negative results15. In the meta-analysis published by Ad-
ams et al. sensitivity of this method is 70 – 88%20. In the
evaluation of 17 studies on EBUS-TBNA method con-
ducted by the American College of Chest Physician
(ACCP), it showed 24% false negative results15.
Due to its suboptimal negative predictive value, the
ACCP recommends if EBUS-TBNA findings are non ma-
lignant, mediastinoscopy should be performed to confirm
them14.
Esophageal Endoscopic Ultrasound with
Needle Biopsy (EUS-FNA)
This technique is limited by poor access to the upper
mediastinal lymph nodes, which are the most common
sites for metastases in lymph nodes. It is still useful in
the evaluation of lower mediastinal lymph nodes (nodal
positions 8 and 9) and can therefore be combined with
EBUS and mediastinoscopy15. Needle biopsy of media-
stinal lymph nodes through the esophageal wall can be
done with minimal risk of infection.
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Conclusion
For an optimal therapeutic approach to patients suf-
fering from lung cancer it is necessary to determine the
stage of disease. In the absence of distant metastases,
mediastinal lymph node status is crucial in the therapeu-
tic strategy. Status of lymph nodes determined by non-
invasive staging requires histological confirmation.
For invasive staging videomediastinoscopy and EBUS-
-TBNA have by far the highest sensitivity and the lowest
percentage of false negative results. Recommendation of
medical associations involved in treatment of lung cancer
(ACCP, ESTS, AATS) is to use videomediastinoscopy or
EBUS-TBNA for staging of patients with discretely in-
creased mediastinal lymph nodes. In case of negative
EBUS-TBNA findings, mediastinoscopy should be per-
formed to confirm these findings.
In patients whose lymph nodes are not enlarged vi-
deomediastinoscopy is preferred method because of its
greater sensitivity and lower percentage of false negative
results, although EBUS-TBNA comes to mind if confir-
mation of the negative result with videomediastinoscopy
is planned.
In patients with clinical N2 disease videomediastino-
scopy is preferred method to exclude N3 disease. Given
the high percentage of false negative results of EBUS-
-TBNA if lymph nodes are not enlarged N3 disease can be
overlooked in 24% cases using this method.
And last but not least, there is the issue of costs of
both methods. Equipment for videomediastinoscopy is
significantly less expensive than one for EBUS which is,
in terms of county hospitals, extremely important item.
From the foregoing it is evident that videomediasti-
noscopy is a method of choice for invasive staging of the
primary non – small cell lung cancer.
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ULOGA VIDEOMEDIJASTINOSKOPIJE U ODRE\IVANJU STADIJA PRIMARNOG
NE-SITNOSTANI^NOG RAKA PLU]A
S A @ E T A K
Rak plu}a je naj~e{}a maligna bolest i vode}i uzrok smrti od malignih bolesti u svijetu a njegova incidencija je u
porastu. U trenutku postavljanja dijagnoze ve}ina bolesnika ima uznapredovalu bolest i nisu kandidati za radikalno
kirur{ko lije~enje. Bolesnici koji nemaju udaljene metastaze podvrgavaju se brojnim dijagnosti~kim metodama u svrhu
otkrivanja metastaza u limfnim ~vorovima medijastinuma koji ~ine drena`ni put limfe iz plu}a. Za otkrivanje meta-
staza u limfnim ~vorovima medijastinuma izvodi se vi{e invazivnih dijagnosti~kih procedura od kojih su najpouzdanije
videomedijastinoskopija i endobronhijalni ultrazvuk sa transtrahealnom punkcijom. Kirur{ko lije~enje je terapija iz-
bora u odsustvu metastaza u limfnim ~vorovima medijastinuma, dok se u suprotnom provodi multimodalno lije~enje.
Na Odsjeku torakalne kirurgije Op}e bolnice Zadar videomedijastinoskopija se radi u svrhu odre|ivanja stadija pri-
marnog ne-sitnostani~nog raka plu}a rutinski od rujna 2009. godine.
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